まとめ
フィブロブラスト肺細胞因子は,表面活性物質の産生を刺激することによって,胎児の肺成熟に重要な役割を果たします. この因子を遮断すると,肺の発達が遅れて,その生理学的重要性が確認される.
科学分野:
- バイオケミストリー バイオケミストリー
- 発達生物学 発達生物学とは
- 細胞生物学 細胞生物学
背景:
- 胎児の肺の成熟は,出生後の呼吸機能にとって極めて重要です.
- グルココルチコイドは表面活性物質の合成を調節しますが,そのメカニズムは間接的です.
- 肺メゼンキムは,グルココルチコイドに反応して,II型細胞を刺激し,線維芽細胞-肺肺細胞因子 (FPF) を産生する.
研究 の 目的:
- ネズミの肺線維芽細胞-肺細胞因子 (FPF) に対するモノクローナル抗体を生成する.
- これらの抗体を用いて,胎児の肺成熟におけるFPFの役割を調査する.
- 産前肺発達における生理学的メディエーターとしてのFPFを確認する.
主な方法:
- ラットFPFに対するモノクローナル抗体を生成するハイブリドトーマの生成.
- 胎児ラット肺培養におけるコルチゾール刺激によるフォスファディチルコリン合成に対する抗体の効果を試験する.
- 抗体注入された胚子子チキの肺成熟を評価する.
主要な成果:
- 2つのモノクローナル抗体は,コルチゾール刺激による表面活性物質の合成を in vitro で減少させた.
- これらの抗体は,II型細胞に対するFPFの刺激効果を阻害した.
- In vivoでは,抗体注射により,胚子子鶏の肺成熟が遅れて,臓器特異性を示した.
結論:
- FPFは,グルココルチコイド誘発の胎児の肺成熟における重要な媒介である.
- FPFに対するモノクローナル抗体は,胎前の肺の発達を阻害することができます.
- これらの発見は,肺発達におけるFPFの重要な生理学的役割を支持しています.
関連する概念動画
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.